Jardiance Reduces Risk of Progressive Kidney Disease in Patients with Type 2 Diabetes
New data showed Jardiance reduced the risk of new-onset or worsening kidney disease by 39% versus placebo when added to standard care in adults with type 2 diabetes with established cardiovascular disease. Boehringer Ingelheim and Lilly announced the findings at the American Diabetes Association (ADA) 76th Scientific Sessions in New Orleans early in the month.